OS Therapies (OSTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OSTX OS Therapies

Watchlist

1.870
-0.190-9.22%

Trading Nov 19 11:00 ET

39.72MMarket Cap-5343P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

OS Therapies 3Q Loss/Shr 18c >OSTX
Dow JonesNov 15 09:50 ET
Express News | OS Therapies Q3 EPS $(0.18) Misses $(0.12) Estimate
BenzingaNov 15 09:49 ET
OS Therapies Anticipates Beginning to Generate Rev Through the Sale of a Priority Review Voucher It Expects to Be Issued by FDA >OSTX
Dow JonesNov 15 09:49 ET
Express News | Os Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
ReutersNov 15 09:47 ET
OS Therapies | 10-Q: Quarterly report
SECNov 15 09:18 ET · Announcements
OS Therapies Files to Sell $15M in Common Stock for Holders
Seeking AlphaNov 12 17:39 ET

Comments

Jaguar8

Sep 11 07:18

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...

Jaguar8

Aug 29 06:53

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...